Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

Damato, Angela; Iachetta, Francesco; Antonuzzo, Lorenzo; Nasti, Guglielmo; Bergamo, Francesca; Bordonaro, Roberto; Maiello, Evaristo; Zaniboni, Alberto; Tonini, Giuseppe; Romagnani, Alessandra; Berselli, Annalisa; Normanno, Nicola; Pinto, Carmine

doi:10.1186/s12885-020-07268-4

BMC Cancer

Article metrics
Last updated: Wed, 24 Apr 2024 13:56:58 Z

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

Access & Citations

3966

Article Accesses
10

Web of Science
11

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com